000279187 001__ 279187
000279187 005__ 20250828101646.0
000279187 0247_ $$2doi$$a10.1002/mds.30169
000279187 0247_ $$2pmid$$apmid:40099366
000279187 0247_ $$2pmc$$apmc:PMC12160969
000279187 0247_ $$2ISSN$$a0885-3185
000279187 0247_ $$2ISSN$$a1531-8257
000279187 037__ $$aDZNE-2025-00715
000279187 041__ $$aEnglish
000279187 082__ $$a610
000279187 1001_ $$00000-0002-8809-8481$$aBehnke, Jennifer K$$b0
000279187 245__ $$aLong-Term Stability of Spatial Distribution and Peak Dynamics of Subthalamic Beta Power in Parkinson's Disease Patients.
000279187 260__ $$aNew York, NY$$bWiley$$c2025
000279187 3367_ $$2DRIVER$$aarticle
000279187 3367_ $$2DataCite$$aOutput Types/Journal article
000279187 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1751967526_3178
000279187 3367_ $$2BibTeX$$aARTICLE
000279187 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000279187 3367_ $$00$$2EndNote$$aJournal Article
000279187 520__ $$aSubthalamic beta oscillations are a biomarker for bradykinesia and rigidity in Parkinson's disease (PD), incorporated as a feedback signal in adaptive deep brain stimulation with potential for guiding electrode contact selection. Understanding their longitudinal stability is essential for successful clinical implementation.We aimed to analyze the long-term dynamics of beta peak parameters and beta power distribution along electrodes.We recorded local field potentials from 12 channels per hemisphere of 33 PD patients at rest, in a therapy-off state at two to four sessions (0, 3, 12, 18-44 months) post-surgery. We analyzed bipolar beta power (13-35 Hz) and estimated monopolar beta power in subgroups with consistent recordings.During the initial 3 months, beta peak power increased (P < 0.0001). While detection of high-beta peaks was more consistent, low- and high-beta peak frequencies shifted substantially in some hemispheres during all periods. Spatial distribution of beta power correlated over time. Maximal beta power across segmented contact levels and directions was significantly stable compared with chance and increased in stability over time. Active contacts for therapeutic stimulation showed consistently higher normalized beta power than inactive contacts (P < 0.0001).Our findings indicate that beta power is a stable chronic biomarker usable for beta-guided programming. For adaptive stimulation, high-beta peaks might be more reliable over time. Greater stability of beta power, center frequency, and spatial distribution beyond an initial stabilization period suggests that the microlesional effect significantly impacts neuronal oscillations, which should be considered in routine clinical practice when using beta activity for automated programming algorithms. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
000279187 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000279187 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000279187 650_7 $$2Other$$aParkinson's disease
000279187 650_7 $$2Other$$abeta band oscillations
000279187 650_7 $$2Other$$adeep brain stimulation
000279187 650_7 $$2Other$$alocal field potentials
000279187 650_7 $$2Other$$asubthalamic nucleus
000279187 650_2 $$2MeSH$$aHumans
000279187 650_2 $$2MeSH$$aParkinson Disease: physiopathology
000279187 650_2 $$2MeSH$$aParkinson Disease: therapy
000279187 650_2 $$2MeSH$$aMale
000279187 650_2 $$2MeSH$$aDeep Brain Stimulation: methods
000279187 650_2 $$2MeSH$$aBeta Rhythm: physiology
000279187 650_2 $$2MeSH$$aSubthalamic Nucleus: physiopathology
000279187 650_2 $$2MeSH$$aFemale
000279187 650_2 $$2MeSH$$aMiddle Aged
000279187 650_2 $$2MeSH$$aAged
000279187 7001_ $$00000-0002-8738-5825$$aPeach, Robert L$$b1
000279187 7001_ $$aHabets, Jeroen G V$$b2
000279187 7001_ $$00000-0002-1280-5928$$aBusch, Johannes L$$b3
000279187 7001_ $$aKaplan, Jonathan$$b4
000279187 7001_ $$00000-0003-2814-3532$$aRoediger, Jan$$b5
000279187 7001_ $$aMathiopoulou, Varvara$$b6
000279187 7001_ $$00000-0003-1290-208X$$aFeldmann, Lucia K$$b7
000279187 7001_ $$aGerster, Moritz$$b8
000279187 7001_ $$aVivien, Juliette$$b9
000279187 7001_ $$aSchneider, Gerd-Helge$$b10
000279187 7001_ $$aFaust, Katharina$$b11
000279187 7001_ $$00000-0001-9063-0556$$aKrause, Patricia$$b12
000279187 7001_ $$0P:(DE-2719)2811089$$aKühn, Andrea A$$b13$$eLast author$$udzne
000279187 773__ $$0PERI:(DE-600)2041249-6$$a10.1002/mds.30169$$gVol. 40, no. 6, p. 1070 - 1084$$n6$$p1070 - 1084$$tMovement disorders$$v40$$x0885-3185$$y2025
000279187 8564_ $$uhttps://pub.dzne.de/record/279187/files/DZNE-2025-00715%20SUP.docx
000279187 8564_ $$uhttps://pub.dzne.de/record/279187/files/DZNE-2025-00715.pdf$$yOpenAccess
000279187 8564_ $$uhttps://pub.dzne.de/record/279187/files/DZNE-2025-00715.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000279187 8564_ $$uhttps://pub.dzne.de/record/279187/files/DZNE-2025-00715%20SUP.doc
000279187 8564_ $$uhttps://pub.dzne.de/record/279187/files/DZNE-2025-00715%20SUP.odt
000279187 8564_ $$uhttps://pub.dzne.de/record/279187/files/DZNE-2025-00715%20SUP.pdf
000279187 909CO $$ooai:pub.dzne.de:279187$$popenaire$$pdnbdelivery$$pdriver$$pVDB$$popen_access
000279187 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811089$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000279187 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000279187 9141_ $$y2025
000279187 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-16
000279187 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-16
000279187 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000279187 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-16
000279187 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOVEMENT DISORD : 2022$$d2024-12-16
000279187 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-16$$wger
000279187 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-16
000279187 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-16
000279187 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-16
000279187 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000279187 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-16
000279187 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOVEMENT DISORD : 2022$$d2024-12-16
000279187 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-16
000279187 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-16
000279187 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-16$$wger
000279187 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-16
000279187 9201_ $$0I:(DE-2719)5000008$$kAG Kühn$$lMovement Disorders (Parkinson's disease, Dystonia)$$x0
000279187 980__ $$ajournal
000279187 980__ $$aVDB
000279187 980__ $$aUNRESTRICTED
000279187 980__ $$aI:(DE-2719)5000008
000279187 9801_ $$aFullTexts